Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute

▴ Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute
Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee).

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). The name was first announced by Swiss regulatory authority, Swissmedic. Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA). The approval of the brand name by other global regulatory agencies will follow their respective guidelines, policies, and procedures.

In a joint press release, BioNTech and Pfizer commented on the vaccine's brand name, "The vaccine will be marketed in the EU under the brand name COMIRNATY®, which represents a combination of the terms COVID-19, mRNA, community, and immunity, to highlight the first authorization of a messenger RNA (mRNA) vaccine, as well as the joint global efforts that made this achievement possible with unprecedented rigor and efficiency, and with safety at the forefront, during this global pandemic."

The COVID-19 vaccine's proposed nonproprietary name (pINN), tozinameran (toe zi na' mer an), was also developed by Brand Institute and its wholly-owned subsidiary, Drug Safety Institute. The "proposed" status of the name indicates the standard 4-month comment period before becoming a recommended INN (rINN). The -meran suffix indicates that this is an mRNA vaccine.

"The entire Brand Institute and Drug Safety Institute team is honored to have partnered with two incredible companies, Pfizer and BioNTech, on the development of their COVID-19 vaccine's brand name, COMIRNATY®, and nonproprietary (p-INN) name, tozinameran," said Brand Institute's Chairman and CEO, James L. Dettore. "Naming a product that will have such a profound global impact is humbling, and an opportunity for which we are truly grateful."

With a portfolio of over 3,300 marketed healthcare names for close to 950 clients, Brand Institute is the global leader in pharmaceutical and healthcare-related name development. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally. Drug Safety Institute is comprised of former naming regulatory officials from global government health agencies, including FDA, EMA, Health Canada, American Medical Association (AMA), and the World Health Organization (WHO).

These regulatory experts co-authored the name review guidelines while with their respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications. Now working for a private company, these professionals provide Brand Institute's clients with industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling.

Tags : #BrandInstituteLatestUpdates #PfizerandBioNTechsCOVID-19vaccine #Pfizer #BioNTech #COMIRNATY #Covid-19Vaccine #mRNA #tozinameran #DrugSafetyInstitute #WHO #FDA #EMA #AmericanMedicalAssociation #governmenthealthagencies

About the Author


Rohit Sharma

Writer, Health Enthusiast, and an Accountant, Rohit Sharma is a writer at medicircle, penning down his thoughts about healthcare research, innovations, trends in healthcare and simply all about healthcare. Write to rohit on [email protected]

Related Stories

Loading Please wait...
-Advertisements-





Trending Now

India Covid Vaccine Rollout : A detailed state wise update Jan 19,2021January 19, 2021
Lakshadweep reports first Covid-19 case January 19, 2021
Country's COVID-19 recovery rate reaches 96.66 per cent; more than 3, 81000 people vaccinated so farJanuary 19, 2021
Biden stays the travel ban for passengers from UK, Brazil and EU countriesJanuary 19, 2021
US faces 400000 lakh deaths due to CoronavirusJanuary 19, 2021
Sirnaomics announces first patient dosed In phase 2a study of STP705January 18, 2021
Andhra Pradesh: 332 locations identified for rollout of COVID-19 vaccinationJanuary 18, 2021
COVID-19 Vaccination begins in Kargil at District HospitalJanuary 18, 2021
Jharkhand: Covid vaccination drive underway at all 49 centresJanuary 18, 2021
Higher coffee intake may be linked to lower prostate cancer riskJanuary 18, 2021
Vaccination drive against Covid-19 being carried out four days a week in West BengalJanuary 18, 2021
Short term low carbohydrate diet linked to remission of type 2 diabetesJanuary 18, 2021
Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancerJanuary 18, 2021
How important is nutrition for health?January 18, 2021
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient solid cancers at ASCO Gastrointestinal Cancers SymposiumJanuary 18, 2021
Avian Influenza confirmed in crow samples from Haridwar, Lansdowne forest range of UttarakhandJanuary 18, 2021
National COVID-19 recovery rate improves to 96.59 per centJanuary 18, 2021
Over 5, 48, 000 COVID samples tested in country in last 24 hoursJanuary 18, 2021
India's vibrant Biotechnology sector ; A failsafe investment optionJanuary 18, 2021
Total 447 adverse events reported during COVID vaccination: Health Ministry January 18, 2021